Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Immunohematology
Volume 33 (2017): Issue 1 (March 2017)
Requires Authentication
Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation
L.L.W. Cooling
L.L.W. Cooling
,
J. Sherbeck
J. Sherbeck
,
J.C. Mowers
J.C. Mowers
and
S.L. Hugan
S.L. Hugan
| Oct 09, 2019
Immunohematology
Volume 33 (2017): Issue 1 (March 2017)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Case Report
Published Online:
Oct 09, 2019
Page range:
15 - 21
DOI:
https://doi.org/10.21307/immunohematology-2019-004
Keywords
checkpoint inhibitor
,
autoantibody
,
anemia
,
cytopenia
© 2017 L.L.W. Cooling et al., published by Sciendo
L.L.W. Cooling
Transfusion Medicine University of Michigan Hospitals Department of Pathology, 2F225 UH-Blood Bank
Ann Arbor, MI, United States
J. Sherbeck
Pathology House Officer IV University of Michigan Department of Pathology
Ann Arbo, United States
J.C. Mowers
Pathology House Officer III University of Michigan Department of Pathology
Ann Arbo, United States
S.L. Hugan
Immunohematology Reference Laboratory University of Michigan Hospitals
Ann Arbor, MI, United States